Category: St. Jude MedicalSyndicate content

Survey: Docs have mixed feelings about Obamacare | MassDevice.com On Call

December 14, 2011 by MassDevice staff

Doctors are torn about health care reform, according to a survey from the Deloitte Center for Health Solutions.

MassDevice On Call

MASSDEVICE ON CALL — Doctors are split when it comes to health care reform, according to a new survey from the Deloitte Center for Health Solutions.

Of the 501 doctors surveyed, 44 percent said the law was "a good start," while another 44 percent said health care reform was "a step in the wrong direction."

Overall, the doctors worried that the new system would increase access to government insurance programs without reducing costs, leaving fewer people uninsured but increasing emergency room wait times and lowering the total quality of care.

Orthopedics players slide after Medicare aims at "unnecessary" procedures

December 12, 2011 by MassDevice staff

The Centers for Medicare & Medicaid Services unveiled a new project targeting "unnecessary" medical device claims last week, sending share prices down for the industry's major players.

CMS logo

Share prices fizzled for a few orthopedic device makers in the days following news of the Centers for Medicare & Medicaid Services' pre-reimbursement review project.

Last week CMS unveiled plans to launch a new pre-payment review program, asking doctors to provide up-front justification for certain medical equipment and types of claims, especially for orthopedic and cardiac devices.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

UPDATE: CardioMEMS CEO on FDA's Champion ruling

December 9, 2011 by MassDevice staff

An FDA advisory panel fails to confirm that the benefits outweigh the risks of a CardioMEMS implantable heart pressure monitor, casting a shadow on St. Jude Medical's potential $375 million buyout.

CardioMEMS

UPDATED Dec. 9, 2011, with comments from CardioMEMS CEO Dr. Jay Yadav, trial results

FDA panel thumbs down on CardioMEMS implantable heart monitor

December 9, 2011 by MassDevice staff

An FDA advisory panel fails to confirm that the benefits outweigh the risks of a CardioMEMS implantable heart pressure monitor, casting a shadow on St. Jude Medical's potential $375 million buyout.

CardioMEMS
St. Jude Medical

An FDA advisory panel decided that CardioMEMS failed to prove that its wireless, implantable heart monitor's benefits outweigh its risks, casting a shadow on a potential $375 million acquisition by St. Jude Medical (NYSE:STJ) – which already owns nearly a fifth of CardioMEMS.

Med-tech stocks rebound after Medicare jolt | Wall Street Beat

December 7, 2011 by MassDevice staff

Shares of medical device-making companies recover from the slide triggered last week by a Medicare pilot program in 11 states that will ask docs for up-front proof that procedures are necessary; also, Boston Scientific a "fast follower?"; do med-tech stocks pass the Buffett Test?; the latest on the scandal at Olympus; and analysts' ups & downs.

MassDevice.com Wall Street Beat

Wall Street investors rebounded from the jolt delivered by the Centers for Medicare & Medicaid Services last week, regaining most of the value lost after the agency announced stiffer rules for its coverage of some medical procedures.

The new pre-reimbursement review program will ask doctors to provide up-front justification for certain medical equipment and types of claims. Set to launch in 11 states next month, it will flip the reimbursement system from the agency's existing "pay-and-chase" method of looking for improper payments after they've already been made.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Med-tech stocks rebound after Medicare jolt

December 7, 2011 by MassDevice staff

Shares of medical device-making companies recover from the slide triggered last week by a Medicare pilot program in 11 states that will ask docs for up-front proof that procedures are necessary.

MassDevice.com Wall Street Beat

Wall Street investors rebounded from the jolt delivered by the Centers for Medicare & Medicaid Services last week, regaining most of the value lost after the agency announced stiffer rules for its coverage of some medical procedures.

The new pre-reimbursement review program will ask doctors to provide up-front justification for certain medical equipment and types of claims. Set to launch in 11 states next month, it will flip the reimbursement system from the agency's existing "pay-and-chase" method of looking for improper payments after they've already been made.

MassDevice.com +7 | MDT to cut $1.2B, Acquisition chatter for SNN, Olympus's fire sale, FDA chemist, Bovie's COO, FDA's artificial pancreas guidance and St. Judes' Quantra win

December 3, 2011 by MassDevice staff

The top seven medical device stories for the week of November 28, 2011.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp